Related Experiment Videos
Gene therapy and the hemophilias
1Department of Medicine, University of North Carolina at Chapel Hill 27599.
JAMA
|January 5, 1994
Summary
Gene therapy is revolutionizing hemophilia treatment by aiming for a cure. Researchers are developing methods to deliver functional genes for Factor VIII and IX, showing promise in animal models.
Area of Science:
- Biotechnology
- Hematology
- Medical Genetics
Background:
- Hemophilia A and B are debilitating hemorrhagic disorders.
- Current treatments manage symptoms but do not offer a cure.
- Gene therapy presents a potential revolutionary approach for hemophilia.
Purpose of the Study:
- To explore the potential of gene therapy for treating hemophilia A and B.
- To review current advancements in gene therapy strategies for hemophilia.
- To assess the feasibility of achieving amelioration or cure through genetic modification.
Main Methods:
- Cloning of factor VIII and IX genes.
- Development of viral (retroviruses, adenoviruses) and nonviral vectors for gene transfer.
- Targeting various cell types including hepatocytes, muscle cells, and fibroblasts for genetic modification.
- Employing ex vivo and in vivo gene delivery approaches.
Main Results:
- Successful demonstration of in vivo gene therapy in a hemophilic animal model.
- Conversion of a severe hemophilic state to a less severe one in treated animals.
- Identification of multiple cell types amenable to genetic modification for antihemophilic protein production.
Conclusions:
- Gene therapy holds significant promise for the amelioration or cure of hemophilia.
- Both ex vivo and in vivo gene delivery methods show potential.
- Further development is needed, but gene therapy represents a therapeutic revolution for hemophilia patients.